Apr 19, 2018 7:00 am EDT Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
Apr 12, 2018 7:00 am EDT Capricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day
Mar 21, 2018 7:00 am EDT Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences
Mar 14, 2018 4:00 pm EDT Capricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
Mar 08, 2018 4:00 pm EST Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on Wednesday, March 14
Feb 22, 2018 1:23 pm EST New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy
Feb 12, 2018 8:00 am EST Capricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular Dystrophy
Feb 05, 2018 11:11 am EST Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
Jan 16, 2018 7:00 am EST Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies